Shiqi Xu

Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Spatiotemporal Distribution Characteristics and Driving Factors of Phytoplankton in the Mainstream of the Yellow River (Shandong Section).

Spatiotemporal Distribution Characteristics and Driving Factors of Phytoplankton in the Mainstream of the Yellow River (Shandong Section).

Journal: Microorganisms
Published: May 14, 2026

Molecular basis for the activation of PAF receptor by PAF.

Molecular basis for the activation of PAF receptor by PAF.

Journal: Cell reports
Published: March 14, 2024

Structure-Based Optimization of One Neutralizing Antibody against SARS-CoV-2 Variants Bearing the L452R Mutation.

Structure-Based Optimization of One Neutralizing Antibody against SARS-CoV-2 Variants Bearing the L452R Mutation.

Journal: Viruses
Published: March 09, 2024

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.

Journal: Frontiers in immunology
Published: March 30, 2022

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein.

Journal: Emerging microbes & infections
Published: December 29, 2021

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.

Journal: Viruses
Published: June 22, 2021

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.

Journal: Vaccine
Published: June 11, 2021

Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody.

Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody.

Journal: EMBO molecular medicine
Published: May 12, 2021

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.

Journal: Cell discovery
Published: April 09, 2021

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.

Journal: Nature communications
Published: August 25, 2020

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.

Journal: Cell discovery
Published: July 13, 2020
Showing 1-11 of 11

Last Updated: 09/26/2026